Compare WAY & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAY | TMDX |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.6B |
| IPO Year | 2023 | 2019 |
| Metric | WAY | TMDX |
|---|---|---|
| Price | $25.06 | $134.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | $37.60 | ★ $144.25 |
| AVG Volume (30 Days) | ★ 3.1M | 620.5K |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 569.23 | 231.17 |
| EPS | 0.61 | ★ 2.28 |
| Revenue | ★ $1,099,278,000.00 | $441,540,000.00 |
| Revenue This Year | $17.99 | $38.73 |
| Revenue Next Year | $10.41 | $20.55 |
| P/E Ratio | ★ $41.10 | $58.88 |
| Revenue Growth | 16.50 | ★ 82.74 |
| 52 Week Low | $21.13 | $62.07 |
| 52 Week High | $45.00 | $156.00 |
| Indicator | WAY | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 47.76 |
| Support Level | $21.13 | $129.73 |
| Resistance Level | $26.29 | $137.49 |
| Average True Range (ATR) | 1.42 | 5.77 |
| MACD | 0.39 | -0.34 |
| Stochastic Oscillator | 72.14 | 38.32 |
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.